Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.
The production of alloreactive cytotoxic T-lymphocytes (CTL) for therapy of recurrent brain tumours was performed in the CELLMAX artificial capillary system composed of cell-culture modules containing cellulose acetate or cuprammonium rayon hollow fibres. Lymphocytes, obtained from the brain-tumour patient to be used for sensitization, were stimulated with OKT3 (anti-CD3) and interleukin-2 (IL-2) and inoculated into the extracapillary space of artificial capillary modules. For allogeneic CTL production, the expanded patient lymphocytes were harvested, irradiated and placed into a second artificial capillary system with allogeneic lymphocytes from a healthy donor. In a one-way mixed lymphocyte reaction, CTL developed in the presence of low-concentration IL-2 (60 i.u. of IL-2/ml). In 18-21 days the cell preparation usually displayed a predominantly CD3+, CD8+ phenotype, which consorted with the dual-labelled CD8/CD11a markers used to identify CTL. Chromium (Cr)-release assays demonstrated lysis of patient tumour in relation to allogeneic glioma; the response observed in cold-target-inhibition assays confirmed lysis of the relevant tumour by the CTL.
Kruse
C A
CA
Department of Immunology, University of Colorado Health Sciences Center, Denver 80262, USA.
Beck
L T
LT
D000911:Antibodies, Monoclonal / Q000276:immunology; D001672:Biocompatible Materials / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000628:therapy*; D017252:CD3 Complex / Q000235:genetics / Q000276:immunology; D016827:CD8 Antigens / Q000235:genetics / Q000276:immunology; D002478:Cells, Cultured; D002482:Cellulose / Q000031:analogs & derivatives / Q000627:therapeutic use; D002857:Chromium / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics / Q000276:immunology; D005910:Glioma / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D016169:Lymphocyte Function-Associated Antigen-1 / Q000235:genetics / Q000276:immunology; D008567:Membranes, Artificial; D016853:Muromonab-CD3 / Q000494:pharmacology; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology* / Q000528:radiation effects; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D001672:Biocompatible Materials; D017252:CD3 Complex; D016827:CD8 Antigens; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D016169:Lymphocyte Function-Associated Antigen-1; D008567:Membranes, Artificial; D016853:Muromonab-CD3; D002857:Chromium; C066013:AM 160H; C005062:acetylcellulose; D002482:Cellulose